[Bone marrow scintigraphy. Principles, clinical results and indications].
After consideration of the anatomical and physiological principles, the radiopharmaceuticals for scintigraphy of the erythropoietic, reticuloendothelial and-as a new development-of the granulopoietic bone marrow are introduced and compared. The data on performing and evaluating bone marrow scans are followed by the presentation of the clinical results. Staging and re-staging of malignant lymphomas, multiple myeloma, breast and lung cancer are considered to be the main indications. 99mTc-labelled monoclonal anti-NCA-95-antibodies are regarded as the radiopharmaceutical of choice.
Munz
D L
DL
Abteilung Nuklearmedizin, Klinikum der Georg-August-Universität, Göttingen.
D001853:Bone Marrow / Q000033:anatomy & histology / Q000000981:diagnostic imaging*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging*; D006801:Humans; D007504:Iron Radioisotopes; D008175:Lung Neoplasms / Q000000981:diagnostic imaging*; D008223:Lymphoma / Q000000981:diagnostic imaging*; D009101:Multiple Myeloma / Q000000981:diagnostic imaging*; D016719:Radioimmunodetection; D013667:Technetium
D007504:Iron Radioisotopes; D013667:Technetium
Knochenmarkszintigraphie. Prinzipien, klinische Ergebnisse und Indikationen.